Your Doctor Said Your Cholesterol Is Fine. Here's Why They Might Be Wrong.

There is a conversation that happens in primary care offices every day across the United States. A patient gets their annual labs back. Their doctor looks at the results and says some version of: “Your cholesterol looks good. LDL is normal. Keep doing what you’re doing.” The patient leaves reassured.

For many of those patients, that reassurance is accurate. For a meaningful subset — estimated at somewhere between 20 and 30 percent of adults with apparently normal LDL cholesterol — it is not.

The problem is not that physicians are being negligent. The problem is that the standard lipid panel, which has been the cornerstone of cardiovascular risk assessment for decades, measures the wrong thing. It measures cholesterol mass — the amount of cholesterol floating in your blood. What actually drives atherosclerosis — the buildup of plaque in arterial walls that leads to heart attacks and strokes — is not cholesterol mass. It is the number of lipoprotein particles carrying that cholesterol, and specifically whether those particles are penetrating arterial walls and depositing their contents there.

This article explains the biomarkers that capture what the standard lipid panel misses — ApoB and Lp(a) — why they matter, and what you can do with that information.

What Your Standard Lipid Panel Actually Measures

When your doctor orders a standard lipid panel, you receive four numbers:

• Total cholesterol — the total amount of cholesterol in your blood across all lipoprotein types
• LDL-C — low-density lipoprotein cholesterol, the amount of cholesterol carried by LDL particles
• HDL-C — high-density lipoprotein cholesterol, the amount of cholesterol carried by HDL particles
• Triglycerides — a separate fat type that reflects dietary carbohydrate intake and metabolic health

The number that gets the most clinical attention is LDL-C. Elevated LDL-C is associated with increased cardiovascular risk, and reducing LDL-C with statins is one of the most well-validated interventions in preventive cardiology. The LDL-C target has been the organizing principle of lipid management guidelines for the better part of four decades.

The problem is that LDL-C is a measure of cholesterol mass — not particle number. And it turns out that particle number is what matters most for cardiovascular risk.

The Particle Number Problem — Why LDL-C Misses the Story

To understand why this matters, it helps to think about how atherosclerosis actually develops.

Atherosclerosis begins when LDL particles — the small, dense lipoproteins that carry cholesterol through the bloodstream — penetrate the endothelial lining of arterial walls. Once inside the arterial wall, LDL particles can become oxidized and trigger an inflammatory response, leading to the formation of foam cells and ultimately atherosclerotic plaque. This process drives coronary artery disease, which causes heart attacks, and carotid artery disease, which causes strokes.

The critical variable in this process is how many LDL particles are circulating — because more particles mean more opportunities for arterial penetration and plaque formation. Particle number drives the risk.

LDL-C does not directly measure particle number. It measures the amount of cholesterol packed inside LDL particles. In most people, those two measures track together reasonably well — if you have a lot of cholesterol, you tend to have a lot of particles, and vice versa. But a significant minority of people have a mismatch between the two. This is called LDL discordance.

LDL Discordance — The 30 Percent Problem

LDL discordance occurs when LDL particle number and LDL cholesterol point in different directions. There are two patterns:

Pattern 1 — High particle number, normal cholesterol. A patient has a normal or even low LDL-C, but their LDL particles are small and dense — carrying less cholesterol per particle than average. Their standard lipid panel looks reassuring. Their actual particle number — and therefore their cardiovascular risk — is elevated. This patient is told their cholesterol is fine. It is not.

Pattern 2 — Normal particle number, high cholesterol. A patient has an elevated LDL-C, but their LDL particles are large and buoyant — carrying more cholesterol per particle than average. Their lipid panel looks alarming. Their actual particle number is more moderate. This patient may be offered statin therapy based on a number that is overestimating their risk.

Research using advanced lipoprotein testing has estimated that LDL discordance affects up to 30 percent of patients — meaning roughly one in three people have a meaningful mismatch between what their standard lipid panel says and what their actual cardiovascular particle burden is.

This is not a small rounding error. It represents a systematic failure of the standard lipid panel to correctly characterize cardiovascular risk in a substantial portion of the population.

ApoB — The Biomarker That Fixes This

Apolipoprotein B — ApoB — is a protein that sits on the surface of every atherogenic lipoprotein particle in your blood. Every LDL particle has exactly one ApoB molecule. Every VLDL particle has exactly one ApoB molecule. Every IDL and lipoprotein(a) particle has exactly one ApoB molecule.

This means that measuring ApoB gives you a direct count of the total number of atherogenic particles circulating in your blood. One ApoB equals one atherogenic particle. It is the cleanest and most direct measure of cardiovascular particle burden available through routine laboratory testing.

The clinical implications are significant. Large-scale epidemiological studies and Mendelian randomization analyses — a type of genetic study that can establish causality rather than just correlation — have consistently shown that ApoB is a stronger predictor of cardiovascular events than LDL-C. The INTERHEART study, one of the largest cardiovascular risk factor studies ever conducted, found that the ApoB to ApoA1 ratio was the single strongest lipid-related predictor of myocardial infarction across 52 countries.

More recently, data from the FOURIER trial — which studied the PCSK9 inhibitor evolocumab in patients with established cardiovascular disease on statin therapy — showed that on-treatment ApoB levels predicted residual cardiovascular risk more precisely than on-treatment LDL-C levels. Patients who achieved the same LDL-C reduction had different residual risks depending on their ApoB — a finding that has reinforced the case for ApoB as the preferred treatment target.

What Your ApoB Number Means

ApoB is measured in milligrams per deciliter (mg/dL). General reference ranges:

ApoB Level	Category	Clinical Interpretation
Below 80 mg/dL	Optimal	Target for most patients with risk factors
80–90 mg/dL	Near optimal	Acceptable for lower-risk individuals
90–110 mg/dL	Borderline high	Warrants clinical review
Above 110 mg/dL	High	Associated with significantly elevated CV risk

For patients with established cardiovascular disease, type 2 diabetes, or multiple risk factors, many preventive cardiologists now target ApoB below 60–70 mg/dL — a more aggressive threshold supported by the residual risk data from major statin and PCSK9 inhibitor trials.

It is worth noting that ApoB is not yet universally incorporated into cardiovascular guidelines — the American College of Cardiology and American Heart Association guidelines still use LDL-C as the primary treatment target, with ApoB listed as an optional confirmatory marker. However, the European Society of Cardiology and several other international bodies have moved more aggressively toward ApoB as a primary target. The evidence base for ApoB is stronger than the current US guideline positioning reflects.

Lp(a) — The Cardiovascular Risk Factor Nobody Told You About

If ApoB is the biomarker that most people have not heard of, Lp(a) — lipoprotein(a), pronounced “L-P-little-a” — is the one that most people have never been tested for and that carries some of the most actionable cardiovascular risk information available.

Lp(a) is a lipoprotein particle structurally similar to LDL but with an additional protein called apolipoprotein(a) — apo(a) — attached to it. This apo(a) attachment gives Lp(a) properties that make it particularly atherogenic. It promotes plaque formation, has pro-thrombotic effects (meaning it contributes to blood clot formation), and is preferentially deposited in arterial walls in ways that standard LDL is not.

It Is Largely Genetic

Approximately 80 to 90 percent of a person’s Lp(a) level is determined by genetics — specifically by the LPA gene on chromosome 6. Diet, exercise, weight loss, and statins have minimal effect on Lp(a) levels. If your Lp(a) is elevated, it was almost certainly elevated at birth and will remain elevated throughout your life regardless of lifestyle modifications.

This genetic determination has an important implication: you cannot lifestyle your way out of elevated Lp(a). Knowing your level allows you to take it into account in your overall cardiovascular risk assessment and pursue interventions — both pharmacological and otherwise — that are appropriate given that risk.

It Affects Approximately 20 Percent of the Population

Approximately 1 in 5 adults has Lp(a) levels above 50 mg/dL — the threshold most commonly used to define clinically elevated Lp(a). At this level and above, Lp(a) is associated with a two- to three-fold increase in the risk of myocardial infarction and a similar increase in the risk of aortic valve stenosis.

Lp(a) levels above 100 mg/dL — sometimes referred to as very high Lp(a) — are associated with cardiovascular risk approaching that of familial hypercholesterolemia, a genetic condition that cardiologists take very seriously.

It Is Not Captured by Your Standard Lipid Panel

Lp(a) particles carry cholesterol, and that cholesterol is included in your total cholesterol and LDL-C measurements — but there is no way to identify the Lp(a) contribution from a standard lipid panel. A patient with an LDL-C of 110 mg/dL might have 40 mg/dL of that cholesterol sitting inside Lp(a) particles — a very different risk profile than a patient with the same LDL-C number and a low Lp(a). Standard testing cannot distinguish between them.

The Treatment Landscape Is About to Change

Until very recently, there were no approved medications specifically targeting Lp(a). That is changing rapidly. Muvalaplin — an oral small molecule inhibitor of Lp(a) — and several RNA-based therapeutics are in late-stage clinical development with PDUFA dates approaching. Olpasiran, a small interfering RNA therapy, has shown reductions in Lp(a) levels of greater than 90 percent in clinical trials.

Knowing your Lp(a) now — before these therapies are approved — positions you to have an informed conversation with your cardiologist about whether you are a candidate for treatment when those options become available.

What Your Lp(a) Number Means

Lp(a) can be reported in mg/dL or nmol/L — the units are not interchangeable and the reference ranges differ. Confirm which unit your lab uses.

Level (mg/dL)	Level (nmol/L)	Risk Category
Below 30	Below 75	Low risk
30–50	75–125	Borderline — interpret with overall risk profile
Above 50	Above 125	Clinically elevated — significantly increased CV risk
Above 100	Above 200	Very high — warrants aggressive risk factor management

How to Get These Tests

Both ApoB and Lp(a) are standard laboratory tests that can be ordered through most clinical laboratories. The challenge is that many primary care physicians do not order them routinely — either because current guidelines do not mandate them or because the clinical visit structure does not support extended lipid discussions.

Ask Your Primary Care Physician

The simplest path is to ask your physician directly: “I would like to know my ApoB and Lp(a) in addition to my standard lipid panel. Can you add those to my labs?” Most physicians will accommodate this request. If your physician is unfamiliar with these tests or dismisses the request, that is useful clinical information about whether your current preventive care is as complete as it should be.

Direct-to-Consumer Lab Testing

Both ApoB and Lp(a) are available through direct-to-consumer lab testing services — meaning you can order them yourself without a physician referral, pay out of pocket, and have blood drawn at a local lab. Services like Ulta Lab Tests and Walk-In Lab offer both tests individually and as part of broader cardiovascular risk panels.

A basic cardiovascular biomarker panel — ApoB, Lp(a), hsCRP, and a standard lipid panel — typically runs $100 to $200 out of pocket through these services. For the clinical information it provides, that is one of the highest-value preventive health investments available.

Advanced Lipid Testing Panels

Some clinical laboratories and direct-to-consumer services offer advanced lipoprotein testing — including LDL particle number by NMR (nuclear magnetic resonance spectroscopy), which provides the same particle count information as ApoB through a different methodology. These panels are more expensive but provide a more granular picture of lipoprotein subclass distribution. For most patients, ApoB alone provides sufficient clinical information without the additional cost.

What to Do With Your Results

Getting the test is only half of the equation. Knowing what to do with the results is where clinical guidance matters.

If your ApoB is elevated: Elevated ApoB is primarily addressed through the same interventions that lower LDL-C — statins, ezetimibe, PCSK9 inhibitors — since these medications reduce the production and increase the clearance of atherogenic particles. Dietary changes, specifically reducing saturated fat intake and replacing it with unsaturated fats, also reduce ApoB. The key clinical point is that treatment targets should be set based on ApoB rather than LDL-C for patients where discordance is suspected.

If your Lp(a) is elevated: Currently, lifestyle modifications do not meaningfully lower Lp(a). The clinical response to elevated Lp(a) involves two things: aggressive management of all other modifiable cardiovascular risk factors (blood pressure, LDL-C/ApoB, smoking, diabetes, inflammation) to offset the added risk from Lp(a), and monitoring for the emergence of Lp(a)-specific therapies that may become available in the near future. PCSK9 inhibitors reduce Lp(a) by approximately 25 percent as a secondary effect.

If both are elevated: This combination — elevated ApoB plus elevated Lp(a) — represents a significantly elevated cardiovascular risk profile that warrants a referral to preventive cardiology and an aggressive approach to all modifiable risk factors. This is not a situation to manage with lifestyle changes alone.

A Note on hsCRP — The Inflammation Marker Worth Adding

While ApoB and Lp(a) are the primary underutilized biomarkers in this discussion, high-sensitivity C-reactive protein (hsCRP) deserves a mention as a third test that adds meaningfully to cardiovascular risk assessment at low cost.

hsCRP is a marker of systemic inflammation. Chronic low-grade inflammation — the kind that does not produce obvious symptoms — is a significant driver of atherosclerosis progression and cardiovascular risk. The JUPITER trial demonstrated that patients with normal LDL-C but elevated hsCRP had significantly reduced cardiovascular events when treated with rosuvastatin — a finding that led to the recognition of elevated hsCRP as an independent cardiovascular risk factor even in patients with apparently normal lipid panels.

hsCRP Level	Cardiovascular Inflammatory Risk
Below 1.0 mg/L	Low
1.0–3.0 mg/L	Moderate
Above 3.0 mg/L	High — warrants clinical attention even with normal LDL-C